title: Significant improvement in overall survival among patients diagnosed with low-risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors.
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
authors.forename: Ang
authors.initials: A
authors.lastname: Li
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.|The Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, USA.
authors.forename: Sarvari V
authors.initials: SV
authors.lastname: Yellapragada
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.|The Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, USA.
authors.forename: Martha
authors.initials: M
authors.lastname: Mims
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.|The Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Frolov
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.|The Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, USA.
authors.forename: Gustavo A
authors.initials: GA
authors.lastname: Rivero
mesh_terms: D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D016016:Proportional Hazards Models; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors
keywords: cytokine; myelodysplasia; selective serotonin reuptake inhibitor; serotonin.